Current volume (CHAARTED) and risk (LATITUDE) criteria have long guided treatment decisions for patients with metastatic castration-sensitive prostate cancer (mCSPC). However, the introduction of advanced imaging techniques such as PSMA PET, which offers greater accuracy and earlier detection of metastatic disease, raises questions about the continued relevance of these criteria. ...
mHSPC/mCSPC
Advertisement
In the final segment, the panel emphasizes the importance of trust in the patient-provider relationship.
The panel exchanges strategies on sequencing and debates the potential of immunotherapy in prostate cancer.
In part four, the panel shares thoughts on the implications of recent trials including ARASENS, ARANOTE, and PEACE-3.
The panel discusses nuances to consider when using PSMA PET imaging, including differentiating false positives.
Experts discuss managing prostate cancer progression, risk stratification, and balancing treatment with quality of life.
Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
Advertisement
Prostate Cancer Knowledge Hubs
Conference Coverage
Dr. Keizman showcases his research on using Decipher for early prostate cancer for USA versus non-USA populations.
Dr. Ghoreifi characterizes the activity of inflammasome genes and their association with oncological outcomes in PC.
Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.
EV+P continues to show superior efficacy and durable responses in previously untreated locally advanced or metastatic UC.
The study found promising results with lenvatinib + belzutifan for patients with previously treated RCC.
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.